Stelara ustekinumab: Phase III data

The double-blind, international Phase III IM-UNITI maintenance trial in 388 patients with moderate to severe CD who achieved a clinical response to Stelara in the 8-week

Read the full 268 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE